Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Short-term antibody response and tolerability after one dose of BNT162b2 vaccine in patients receiving hemodialysis: A report from the Quebec Renal Network COVID-19 study

Rémi Goupil, Mehdi Benlarbi, William Beaubien-Souligny, Annie-Claire Nadeau-Fredette, Debashree Chatterjee, Guillaume Goyette, Caroline Lamarche, Alexander Tom, Andrés Finzi, View ORCID ProfileRita S. Suri on behalf of the Réseau Rénal Québécois (Quebec Renal Network) COVID-19 Study Investigators
doi: https://doi.org/10.1101/2021.03.30.21254652
Rémi Goupil
1Hôpital du Sacré-Cœur de Montréal, Montréal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mehdi Benlarbi
2Centre de Recherche du CHUM, Montréal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Beaubien-Souligny
2Centre de Recherche du CHUM, Montréal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annie-Claire Nadeau-Fredette
3Centre de recherche de l’Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Debashree Chatterjee
2Centre de Recherche du CHUM, Montréal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guillaume Goyette
2Centre de Recherche du CHUM, Montréal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Lamarche
3Centre de recherche de l’Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Tom
4Research Institute of the McGill University Health Center, Montreal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrés Finzi
2Centre de Recherche du CHUM, Montréal, QC, Canada
5Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC, Canada
6Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rita S. Suri
2Centre de Recherche du CHUM, Montréal, QC, Canada
5Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC, Canada
7Department of Medicine, McGill University, Montreal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rita S. Suri
  • For correspondence: rita.suri@mcgill.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Patients receiving in-center hemodialysis (HD) are at high risk of exposure to SARS-CoV-2 with high mortality, and response to vaccination is uncertain.

Methods We obtained serial plasma from 58 HD patients and 32 health-care workers (HCW) before and after vaccination with one dose of the BNT162b2 mRNA vaccine; as well as convalescent plasma from 11 HD patients who survived COVID-19. Anti-RBD (region binding domain of the SARS-CoV-2 Spike protein) IgG and IgM levels were measured by ELISA. Groups were stratified by evidence of prior SARS-CoV-2 infection.

Results In HD patients without prior SARS-CoV-2, antiRBD levels were significantly lower at 4 and 8 weeks after vaccination, compared to in HCWs after 3 weeks (p<0.001), and to convalescent plasma (p=0.002). Anti-RBD IgG was non-detectable in 29/46 (63%) of HD, compared to 1/16 (6%) of HCWs (p<0.0001). No patient with non-detectable levels at 4 weeks developed antiRBD by 8 weeks. In HD patients with prior SARS-CoV-2, mean 8-week anti-RBD IgG levels were similar to controls at 3 weeks (p=0.16), and to convalescent plasma (p=0.45). No patients reported symptoms 7 days after vaccination on a standardized questionnaire.

Interpretation While the BNT162b2 vaccine was well-tolerated in hemodialysis patients, a single dose failed to elicit a humoral immune response in the majority of SARS-CoV-2 naïve patients even after prolonged observation. In those with prior SARS-CoV-2 infection, the humoral response after vaccination was delayed. Whether HD patients develop T-cell responses requires further study. Until then, we advise the second dose be administered to all HD patients at the recommended 3-week time interval, and that rigorous SARS-CoV-2 infection prevention and control measures be continued in dialysis units until vaccine efficacy is proven.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by the Canadian Institutes of Health Research (CIHR) Rapid Research COVID-19 funding opportunity. This work was also supported by le Ministère de l'Économie et de l'Innovation du Québec, Programme de soutien aux organismes de recherche et d'Innovation to AF, by the Fondation du CHUM and by a CIHR Foundation Grant #352417 to AF. RS, RG, ACNF, and WBS are supported by the Fonds de Recherche du Québec Santé (FRQS) Clinician-Researcher Awards. AF is the recipient of Canada Research Chair on Retroviral Entry no. RCHS0235950-232424.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Comité d'éthique de la recherche clinique du CR-CHUM and l'Hôpital Sacre-Coeur

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* co-first author

  • ↵** co-senior author

  • Funding: This study was funded by a Canadian Institutes of Health Research (CIHR) Rapid Research COVID-19 funding opportunity. This work was also supported by le Ministère de l’Économie et de l’Innovation du Québec, Programme de soutien aux organismes de recherche et d’innovation to AF, by the Fondation du CHUM and by a CIHR Foundation Grant #352417 to AF.

  • Disclosures : None.

  • This manuscript has been updated with 8-week data. Figure 1 and Table 1 have been revised.

Data Availability

De-identified aggregate data is available upon request to the lead author, RS (rita.sur{at}mcgill.ca), provided the necessary institutional approvals are received. Further information on the assays used and requests for reagents should be directed to and will be fulfilled by AF (andres.finzi{at}umontreal.ca).

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted April 08, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Short-term antibody response and tolerability after one dose of BNT162b2 vaccine in patients receiving hemodialysis: A report from the Quebec Renal Network COVID-19 study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Short-term antibody response and tolerability after one dose of BNT162b2 vaccine in patients receiving hemodialysis: A report from the Quebec Renal Network COVID-19 study
Rémi Goupil, Mehdi Benlarbi, William Beaubien-Souligny, Annie-Claire Nadeau-Fredette, Debashree Chatterjee, Guillaume Goyette, Caroline Lamarche, Alexander Tom, Andrés Finzi, Rita S. Suri
medRxiv 2021.03.30.21254652; doi: https://doi.org/10.1101/2021.03.30.21254652
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Short-term antibody response and tolerability after one dose of BNT162b2 vaccine in patients receiving hemodialysis: A report from the Quebec Renal Network COVID-19 study
Rémi Goupil, Mehdi Benlarbi, William Beaubien-Souligny, Annie-Claire Nadeau-Fredette, Debashree Chatterjee, Guillaume Goyette, Caroline Lamarche, Alexander Tom, Andrés Finzi, Rita S. Suri
medRxiv 2021.03.30.21254652; doi: https://doi.org/10.1101/2021.03.30.21254652

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Nephrology
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (496)
  • Anesthesia (106)
  • Cardiovascular Medicine (1105)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (505)
  • Epidemiology (9792)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2326)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1566)
  • Health Policy (737)
  • Health Systems and Quality Improvement (607)
  • Hematology (238)
  • HIV/AIDS (507)
  • Infectious Diseases (except HIV/AIDS) (11665)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2151)
  • Nursing (134)
  • Nutrition (340)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (519)
  • Oncology (1184)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (221)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (313)
  • Pediatrics (698)
  • Pharmacology and Therapeutics (302)
  • Primary Care Research (268)
  • Psychiatry and Clinical Psychology (2193)
  • Public and Global Health (4680)
  • Radiology and Imaging (784)
  • Rehabilitation Medicine and Physical Therapy (458)
  • Respiratory Medicine (625)
  • Rheumatology (275)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (211)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)